Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ObvioHealth Is Building A New Digital Ecosystem To 'Revolutionize' Trials

Executive Summary

Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.

You may also be interested in...



RedHill Could Soon Seek EUA For COVID-19 Therapy

The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.

New Training Methods Could Reduce Bias In Artificial Intelligence

A “federated” training method could be used to reduce bias in AI, according to one expert on patient safety.

Exec Chat: Cumulus Neuroscience Help Trials Collect Previously Underutilized, Vital Data

Cumulus Neuroscience, previously known as BrainWaveBank, announced a £6m financing round to help develop its unique neurological data collection system.

Topics

UsernamePublicRestriction

Register

MT143811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel